Comparison of radiosensitization by 41 degrees C hyperthermia during low dose rate irradiation and during pulsed simulated low dose rate irradiation in human glioma cells
Gp. Raaphorst et al., Comparison of radiosensitization by 41 degrees C hyperthermia during low dose rate irradiation and during pulsed simulated low dose rate irradiation in human glioma cells, INT J RAD O, 44(1), 1999, pp. 185-188
Citations number
24
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Purpose: Long duration mild hyperthermia has been shown to be an effective
radiosensitizer when given concurrently with low dose rate irradiation, Pul
sed simulated low dose rate (PSLDR) is now being used clinically, and we ha
ve set out to determine whether concurrent mild hyperthermia can be an effe
ctive radiosensitizer for the PSLDR protocol,
Materials and Methods: Human glioma cells (U-87MG) were grown to plateau ph
ase and treated in plateau phase in order to minimize cell cycle redistribu
tion during protracted treatments. Low dose rate (LDR) irradiation and 41 d
egrees C hyperthermia were delivered by having a radium irradiator inside a
temperature-controlled incubator. PSLDR was given using a 150 kVp X-ray un
it and maintaining the cells at 41 degrees C between irradiations. The dura
tion of irradiation and concurrent heating depended on total dose and exten
ded up to 48 h,
Results: When 41 degrees C hyperthermia was given currently with LDR or PSL
DR, the thermal enhancement ratios (TER) were about the same if the average
dose rate for PSLDR was the same as for LDR. At higher average dose rates
for PSLDR the TERs became less.
Conclusions: Our data show that concurrent mild hyperthermia can be an effe
ctive sensitizer for PSLDR, This sensitization can be as effective as for L
DR if the same average dose rate is used and the TER increases with decreas
ing dose rate. Thus mild hyperthermia combined with PSLDR may be an effecti
ve clinical protocol. (C) 1999 Elsevier Science Inc.